
    
      This is a multicenter, open-label, randomized, Phase II study of MM-121 in patients with
      platinum resistant or refractory recurrent/advanced ovarian cancers. Up to 210 patients will
      be randomized (2:1) to receive MM-121 plus paclitaxel or paclitaxel alone.
    
  